research Emerging Treatments in Alopecia
New alopecia treatments aim for better results and fewer side effects.
Search
for
Sort by
Research
180-210 / 419 results 
research Hair Loss in Lichen Planopilaris and Frontal Fibrosing Alopecia: Not Always Irreversible
Hair loss from conditions like LPP and FFA can potentially be reversed with the right treatment.
research Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Alopecia Areata: Genetic and Immunological Insights
Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
research Review of the 2024 American Academy of Dermatology Annual Meeting
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: Evidence to Date
Baricitinib is a promising treatment for alopecia areata.
research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Drug Armamentarium for Alopecia Areata
No cure exists for alopecia areata, and treatments are personalized.
research IL-15 Prolongs Hair Growth and Acts as a Guardian of Human Hair Follicle Immune Privilege
IL-15 helps maintain hair growth and protects the immune status of hair follicles.
research Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
research The Development of Oral Hairy Leukoplakia During JAK Inhibitor Baricitinib Therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
research Tofacitinib Citrate Alleviates Alopecia Universalis Symptoms in Recent Case Study
Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Particulate Matter Induces Inflammatory Response in Human Outer Root Sheath Cells via Oxidative Stress-Dependent MAPK and JAK-STAT Signaling Pathways
Particulate matter causes inflammation in hair cells, potentially harming hair growth.
research A New Era for Alopecia Areata: New Treatments and Improved Knowledge of the Condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Alopecia Areata: Current Understanding and Management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Perifolliculitis Capitis Abscedens Et Suffodiens Treatment With Tumor Necrosis Factor Inhibitors and Baricitinib: A Case Report and Literature Review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.